Progress in CRISPR/Cas9 for CAR-T cell therapy of tumors

doi:10.16352/j.issn.1001-6325.2023.08.1313

Abstract

Abstract: CRISPR/Cas9 gene editing technology can effectively solve the problem of insufficient source of T cells in chimerical antigen receptor-T (CAR-T) therapy and enhance their anti-tumor abilities by knocking out the genes related to the suppression of T cells activity. The technology can also be used to construct T cells with dual-targeting effect to stop tumor immune escape and inhibit recurrence and drug resistance development during chemotherapy. Compared with the other genetic engineering technologies that have complex processes, multiple genome editing by CRISPR/Cas9 is a technology of efficient and convenient to operate.So it is believed to be valuable and potential target molecules for CAR-T therapy.

Key words: CAR-T cells, CRISPR/Cas9, immunotherapy

CLC Number:

WU Qi, WANG Shaobo. Progress in CRISPR/Cas9 for CAR-T cell therapy of tumors[J]. Basic & Clinical Medicine, 2023, 43(8): 1313-1316.

References 25

[1]	Zhou X, Tu S, Wang C, et al. Phase Ⅰ trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas[J]. Front Immunol, 2020, 11: 564099. doi: 10.3389/fimmu.2020.564099.
[2]	Roddie C, Dias J, O'Reilly MA, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia[J]. J Clin Oncol, 2021, 39: 3352-3363.
[3]	Haas AR, Tanyi JL, O'Hara MH, et al. Phase Ⅰ study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers[J]. Mol Ther, 2019, 27: 1919-1929.
[4]	Adusumilli PS, Zauderer MG, Rivière I, et al. A phase Ⅰ trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab[J]. Cancer Discov, 2021, 11: 2748-2763.
[5]	Heczey A, Courtney AN, Montalbano A, et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis[J]. Nat Med, 2020, 26: 1686-1690.
[6]	Katz SC, Hardaway J, Prince E, et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases[J]. Cancer Gene Ther, 2020, 27: 341-355.
[7]	Zhang Y, Zhang Z, Ding Y, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients[J]. J Cancer Res Clin Oncol, 2021, 147: 3725-3734.
[8]	Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase Ⅰ clinical trial[J]. Cytotherapy, 2020, 22: 573-580.
[9]	Wang Q, Zhong X, Li Q, et al. CRISPR-Cas9-mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice[J]. Mol Ther Methods Clin Dev, 2020, 18: 520-531.
[10]	Guo P, Yang J, Huang J, et al. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel[J]. Proc Natl Acad Sci U S A, 2019, 116: 18295-18303.
[11]	Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition[J]. Clin Cancer Res, 2017, 23: 2255-2266.
[12]	Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J]. Nature, 2017, 543: 113-117.
[13]	Hu W, Zi Z, Jin Y, et al. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions[J]. Cancer Immunol Immunother, 2019, 68: 365-377.
[14]	Ruste V, Goldschmidt V, Laparra A, et al. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry[J]. Eur J Cancer, 2021, 158: 217-224.
[15]	Gargett T, Yu W, Dotti G, et al. GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade[J]. Mol Ther, 2016, 24: 1135-1149.
[16]	Zhang Y, Zhang X, Cheng C, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells[J]. Front Med, 2017, 11: 554-562.
[17]	Giuffrida L, Sek K, Henderson MA, et al. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy [J]. Nat Commun, 2021, 12: 3236. doi: 10.1038/s41467-021-23331-5.
[18]	Jung IY, Kim YY, Yu HS, et al. CRISPR/Cas9-mediated knockout of DGK improves antitumor activities of human T cells[J]. Cancer Res, 2018, 78: 4692-4703.
[19]	Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts[J]. Blood, 2019, 133: 697-709.
[20]	Liu S, Deng B, Yin Z, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation[J]. Am J Hematol, 2021, 96: 671-679.
[21]	Liu Y, Deng B, Hu B, et al. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma[J]. Blood Adv, 2022, 6: 717-730.
[22]	Dai H, Wu Z, Jia H, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia[J]. J Hematol Oncol, 2020, 13: 30. doi: 10.1186/s13045-020-00856-8.
[23]	Cordoba S, Onuoha S, Thomas S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial[J]. Nat Med, 2021, 27: 1797-1805.
[24]	Hu Y, Zhou Y, Zhang M, et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Clin Cancer Res, 2021, 27: 2764-2772.
[25]	Zanetti SR, Velasco-Hernandez T, Gutierrez-Agüera F, et al. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL[J]. Mol Ther, 2022, 30: 550-563.